Sami Labs, a subsidiary Sabinsa Corporation has successfully concluded its patent infringement lawsuit against Prakruti Products Private Limited. A proposed Final Consent Judgment, agreed by the parties, was submitted to the United States District Court in New Jersey on February 18, 2015.

The lawsuit, filed in the US District Court, New Jersey on July 30, 2014, alleged Prakruti was selling products that infringed upon Sabinsa’s Curcumin C3 Complex^® US Patent 5,861,415, which protects compositions, methods of use, and methods of extraction of a nutritional supplement in the US.

In addition to any undisclosed monetary settlement, Prakruti has agreed to discontinue any and all future sales of Curcumin to outside distribution. The proposed Final Consent Judgment stipulates that the ’415 Patent was valid, enforceable, and properly issued by the US Patent and Trademark Office. Sabinsa has patents related to Curcumin both in the United States and Europe. In the US, Sabinsa continues to litigate the willful infringement of the ’415 patent by HerbaKraft, Inc., NutriBioLink LLC, and Olive Lifesciences Private Limited. In Germany, Sabinsa continues to litigate a European Curcumin patent infringed by Olive Lifesciences.

"Both sides of this suit favored resolution and came to terms that were more than amicable, while the agreement also sustains Sabinsa’s Curcumin patent to the highest degree,” said Dr. Muhammed Majeed, founder and chairman, Sami Labs and Sabinsa Group.

“This settlement sends a clear message to all suppliers on foreign soil that Sabinsa is very serious about defending its’ patents. This win clearly shows that sitting in India while violating our Curcumin patent, does not mean you can escape IP theft consequences. We also see this as a win for our customers and their consumers alike, because the Curcumin C3 Complex^® brand has been defended and protected,” he added.